Publications by authors named "Y Hosono"
Background/aim: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.
Patients And Methods: This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021.
Article Synopsis
- Invariant natural killer T (iNKT) cells are unique T cells that recognize lipid antigens through a molecule called CD1d, with α-galactosylceramide (α-GalCer) being the strongest known antigen.
- Researchers created a specialized system using supercritical fluid chromatography tandem mass spectrometry (SFC/MS/MS) to separate and identify different forms of hexosylceramide.
- Their findings revealed that α-GalCer, previously not found in mammals, is present in various biological fluids, representing the first identification of this potent antigen in mammalian systems.
Article Synopsis
- - Neuromuscular signal transmission is disrupted in diseases like myasthenia gravis and congenital myasthenic syndromes, prompting research using an ATF2-luciferase system to find compounds that enhance AChR clustering.
- - Four chemical compounds with similar structures significantly boosted luciferase activities, outperforming disulfiram—a known drug—while enhancing AChR clusters in muscle cells without causing toxicity up to 1 μM concentrations.
- - Despite increased phosphorylation of MuSK by some compounds, they likely don't bind directly to MuSK or its associated proteins, indicating further exploration is needed to identify their exact targets for developing new treatments for neuromuscular junction disorders.
Progressive pulmonary fibrosis (PPF), defined as the worsening of various interstitial lung diseases (ILDs), currently lacks useful biomarkers. To identify novel biomarkers for early detection of patients at risk of PPF, we performed a proteomic analysis of serum extracellular vesicles (EVs). Notably, the identified candidate biomarkers were enriched for lung-derived proteins participating in fibrosis-related pathways.
View Article and Find Full Text PDFBackground: Novel biomarkers (BMs) are urgently needed for bronchial asthma (BA) with various phenotypes and endotypes.
Objective: We sought to identify novel BMs reflecting tissue pathology from serum extracellular vesicles (EVs).
Methods: We performed data-independent acquisition of serum EVs from 4 healthy controls, 4 noneosinophilic asthma (NEA) patients, and 4 eosinophilic asthma (EA) patients to identify novel BMs for BA.